A Phase 4 interventional study of Cyclosporine (Sandimmun® i.v.) and Cyclosporine (Sandimmun® Optoral) in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-03-07.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this exploratory study is to evaluate the rejection rate in patients treated with cyclosporine (CsA) preceding oral administration of cyclosporine micro emulsion in de novo liver recipients. The blood levels of CsA and CsA micro emulsion will be monitored by C-2h monitoring. In addition, this study will assess the safety of this treatment regimen.
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Drug: Cyclosporine (Sandimmun® i.v.) · Drug: Cyclosporine (Sandimmun® Optoral)
Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Also known as: Sandimmun
Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
Also known as: Sandimmun
Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation
Number of patients with biopsy proven acute rejection (BPAR) within 3 months after post de novo liver transplantation. In all suspected rejection episodes an allograft biopsy was performed within a 48 hour period of initiation of an anti-rejection therapy. A designated pathologist graded the biopsies according to the Banff criteria into mild, moderate or severe BPAR.
Time frame: 3 months
Incidence, Safety and Tolerability of Cyclosporine Intravenous (i.v.) During 6 Months Post de Novo Liver Transplantation
The secondary efficacy endpoints included: the incidence of BPAR at 6 months; the incidence of treated acute rejection (TAR) / steroid-resistant acute rejection at 3 and 6 months; the incidence of BPAR with moderate/severe histological grading at 3 and 6 months; time to the first BPAR, the first TAR / steroid-resistant acute rejection and BPAR with moderate/severe histological grading; patient death at 3 and 6 months; and graft loss at 3 and 6 months.
Time frame: 3 or 6 months after transplantation
| Milestone | Cyclosporine (Sandimmun®) |
|---|---|
| Started | 34 |
| Patients treated with sandimmun® i.v. | 34 |
| Patients treated with sandimmun® optoral | 29 |
| Completed | 18 |
| Not completed | 16 |
| Withdrew: Adverse event | 5 |
| Withdrew: Abnormal lab value | 1 |
| Withdrew: Unsatisfactory therapeutic effect | 4 |
| Withdrew: No longer requires study drug | 1 |
| Withdrew: Death | 3 |
| Withdrew: Graft loss | 2 |
Number of patients with biopsy proven acute rejection (BPAR) within 3 months after post de novo liver transplantation. In all suspected rejection episodes an allograft biopsy was performed within a 48 hour period of initiation of an anti-rejection therapy. A designated pathologist graded the biopsies according to the Banff criteria into mild, moderate or severe BPAR.
| Participants | Cyclosporine (Sandimmun®) |
|---|---|
| patients with BPAR within 3 months after Tx : YES | 8 |
| patients with BPAR within 3 months after Tx : NO | 26 |
The secondary efficacy endpoints included: the incidence of BPAR at 6 months; the incidence of treated acute rejection (TAR) / steroid-resistant acute rejection at 3 and 6 months; the incidence of BPAR with moderate/severe histological grading at 3 and 6 months; time to the first BPAR, the first TAR / steroid-resistant acute rejection and BPAR with moderate/severe histological grading; patient death at 3 and 6 months; and graft loss at 3 and 6 months.
| Participants | 3 Months After Transplantation | 6 Months After Transplantation |
|---|---|---|
| Patients with BPAR : YES | NA | 10 |
| Patients with BPAR : NO | NA | 24 |
| Patients with TAR : YES | 7 | 8 |
| Patients with TAR : NO | 27 | 26 |
| Patients w/ steroid-resistant acute rejection:YES | 2 | 3 |
| Patients w/ steroid-resistant acute rejection:NO | 32 | 31 |
| BPAR w/ moderate/severe histological grading:YES | 4 | 4 |
| BPAR w/ moderate/severe histological grading:NO | 30 | 30 |
| Occurence of Death : YES | 3 | 3 |
| Occurence of Death : NO | 31 | 31 |
| Occurence of Graft loss : YES | 3 | 3 |
| Occurence of Graft loss : NO | 31 | 31 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine (Sandimmun® i.v.) | — | 18/34 (52.9%) | 34/34 (100%) |
| Cyclosporine (Sandimmun® Optoral) | — | 14/29 (48.3%) | 29/29 (100%) |
| Event | Cyclosporine (Sandimmun® i.v.) | Cyclosporine (Sandimmun® Optoral) |
|---|---|---|
| HAEMORRHAGEVascular disorders | 5/34 | 0/29 |
| CHOLANGITISHepatobiliary disorders | 0/34 | 3/29 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 3/34 | 1/29 |
| ASCITESGastrointestinal disorders | 0/34 | 2/29 |
| BILIARY ISCHAEMIAHepatobiliary disorders | 0/34 | 2/29 |
| INFECTIONInfections and infestations | 0/34 | 2/29 |
| RENAL FAILURERenal and urinary disorders | 2/34 | 2/29 |
| COMPLICATIONS OF TRANSPLANTED LIVERInjury, poisoning and procedural complications | 2/34 | 1/29 |
| POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications | 2/34 | 1/29 |
| RENAL FAILURE ACUTERenal and urinary disorders | 2/34 | 0/29 |
| Event | Cyclosporine (Sandimmun® i.v.) | Cyclosporine (Sandimmun® Optoral) |
|---|---|---|
| CHOLESTASISHepatobiliary disorders | 20/34 | 10/29 |
| ANAEMIABlood and lymphatic system disorders | 18/34 | 10/29 |
| RENAL FAILURERenal and urinary disorders | 18/34 | 7/29 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 17/34 | 2/29 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 17/34 | 2/29 |
| HYPOTENSIONVascular disorders | 17/34 | 4/29 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 16/34 | 4/29 |
| CONSTIPATIONGastrointestinal disorders | 15/34 | 7/29 |
| HYPOALBUMINAEMIAMetabolism and nutrition disorders | 15/34 | 3/29 |
| INSOMNIAPsychiatric disorders | 13/34 | 8/29 |
| Age Continuous(years) | Cyclosporine (Sandimmun®) |
|---|---|
| Mean | 53.2 ± 9.6 |
| Sex: Female, Male(Participants) | Cyclosporine (Sandimmun®) |
|---|---|
| Female | 12 |
| Male | 22 |
The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine